BrightSpring Health Services, Inc. (BTSG) is facing an estimated $600 million in revenue headwinds in 2026 due to changes related to the Inflation Reduction Act and brand-to-generic conversions. The company operates a nationwide integrated pharmacy and provider network, emphasizing home-based care, which serves about 475,000 patients daily. In Q1 2026, Specialty and Infusion revenue rose 36% year over year to $2.64 billion, driven by new drug access and execution.
Management projects ongoing quarterly impacts of approximately $45 million from the Inflation Reduction Act within the Home and Community Pharmacy segment, which saw a revenue decline of 9% to $527 million due to strategic exits from unprofitable customers. However, BTSG raised its 2026 adjusted EBITDA guidance to between $795 million and $825 million, indicating confidence in overcoming these challenges through improved volume and efficiency.
In Provider Services, revenue grew 28% year over year to $442 million, bolstered by expansion and preferred contracts. BrightSpring is strategically focusing on profitability rather than top-line growth amidst a challenging market landscape, positioning itself well to meet payer demand for lower-cost care solutions throughout Medicare, Medicaid, and commercial sectors.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
